What is the 13F Pro Quality Score for SYK?

13F Pro ranks STRYKER CORP (SYK) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SYK's current score at https://13fpro.ai/company/SYK (free sign-up required for the full ranking).

Which hedge funds own the most SYK stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SYK include BlackRock,, VANGUARD CAPITAL MANAGEMENT, JPMORGAN CHASE & CO. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/SYK as soon as new 13F filings post.

Where does 13F Pro source SYK data?

All STRYKER CORP fundamentals and ownership data come directly from SEC EDGAR. STRYKER CORP files with the SEC under CIK 310764. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SYK in?

STRYKER CORP (SYK) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives SYK's revenue?

Per STRYKER CORP's latest 10-Q filed with the SEC on 2026-07-31, the biggest revenue drivers are: MedSurg and Neurotechnology ($3,625M, +9.7% YoY); Orthopaedics ($2,964M, +9.1% YoY); Medical ($1,122M, +13.4% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/SYK.

What are SYK's largest expenses?

STRYKER CORP's latest 10-Q reports these as the largest expense items: Selling, general and administrative ($2,229M, +7.2% YoY); Cost of sales ($2,091M, -4.1% YoY); Research, development and engineering ($434M, +6.6% YoY). Sourced directly from SEC EDGAR filing text for Q2 2026 (quarter ended June 30, 2026).

How often is SYK research updated on 13F Pro?

SYK's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

STRYKER CORP(SYK)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSElarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 310764 SYK stock profile & AI dashboard →

13F Pro Quality Score

72.1/100

Rank #158 of 2,961 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

59.2/100

Profitability

74.9/100

Balance Sheet

80.5/100

Earnings Quality

73.6/100

Free Cash Flow

70.4/100

Institutional Flow

71.2/100

Revenue Scale

94.2/100

Dilution Risk

57.7/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why SYK Scores 72/100

exact factor attribution · 2026-09-11

SYK's composite is driven by scale and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+6.6 pts

94th pct

Profitability

+3.7 pts

75th pct

Free cash flow

+3.1 pts

70th pct

Capital efficiency

+3.0 pts

81th pct

Earnings quality

+2.4 pts

74th pct

Revenue growth

+1.8 pts

59th pct

Institutional flow

+1.1 pts

71th pct

Shareholder dilution

+0.4 pts

58th pct

Earnings growth

-0.0 pts

49th pct

Latest change (2026-07-31): 70 → 67 · ↓ Revenue growth 65→51; ↓ Free cash flow 67→54; despite ↑ Profit margin 70→79

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

SYK Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for STRYKER CORP (SYK), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SYK at 72.1/100 on a 32-signal composite quality model, placing it at rank #158 of 2,961 stocks — the top 10% of the AI-ranked universe. SYK scores in the top quartile across revenue scale (94.2), balance sheet strength (80.5). Based on the latest XBRL financial filings (Q2 2026), STRYKER CORP reports quarterly revenue of $6.6B, net income of $1.3B, an operating margin of 25.2%. Top institutional holders of SYK by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, JPMORGAN CHASE, based on the most recent SEC filings. SYK trades on the NYSE exchange and files with the SEC under CIK 310764. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SYK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for STRYKER CORP directly from SEC EDGAR. STRYKER CORP's 13F Pro composite quality score has ranged between 58 and 74 since 2021, currently 72.1 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about STRYKER CORP

Quirks, history, and lore behind SYK — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · large-cap · listed on NYSE · headquartered in Michigan.
2
The Numbers
Annual revenue around $20 billion, with products sold in over 75 countries — if you've ever been wheeled into an OR, there's a decent chance their gear came along for the ride.
3
The History
Founded in 1941 by an orthopedic surgeon who wanted better tools for his patients — because sometimes the best way to fix healthcare is to literally build the device yourself.
4
The Secret
They don't make pills or run hospitals — they make the implants, surgical robots, and hospital beds that quietly dominate operating rooms and recovery floors worldwide.
5
The Lore
Their Mako robotic surgery system has been used in hundreds of thousands of procedures, and they've spent billions snapping up medical device rivals to stay ahead of the scalpel curve.
6
The Giveaway
An orthopedic surgeon named Homer started it in Kalamazoo, and today their hip and knee replacements are keeping Baby Boomers on the dance floor well past their expiration date.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving SYK's Business? Latest 10-Q Breakdown

✓ 34/34 datapoints verified

AI-extracted from STRYKER CORP's 10-Q filed 2026-07-31 — Q2 2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Net sales rose 9.4% to $6,589M while a $158M reversal of 2025 tariffs helped lift gross margin to 68.3% and operating margin to 25.2%.

Biggest Revenue Drivers

MedSurg and Neurotechnology$3,625M+9.7% YoY

Up 9.2% in constant currency, 9.1% from unit volume and 0.1% from higher prices across most businesses

Orthopaedics$2,964M+9.1% YoY

Constant currency up 8.7%; excluding acquisitions/divestitures up 8.6% from higher shipments across all Orthopaedics businesses

Biggest Revenue Drivers

Total revenue: $6.6B+9.4% YoY

MedSurg and Neurotechnology$3,625M+9.7% YoY

Up 9.2% in constant currency, 9.1% from unit volume and 0.1% from higher prices across most businesses

Within MedSurg and Neurotechnology

Medical$1,122M+13.4% YoY

United States sales up 12.6%, international up 17.9%

Vascular$496M-0.7% YoY

Down 1.8% in constant currency, with United States sales down 6.7%

Orthopaedics$2,964M+9.1% YoY

Constant currency up 8.7%; excluding acquisitions/divestitures up 8.6% from higher shipments across all Orthopaedics businesses

Within Orthopaedics

Trauma and Extremities$1,072M+11.9% YoY

United States sales up 12.5%, international up 10.3%

Largest Expense Items

Selling, general and administrative$2,229M+7.2% YoY

Fell to 33.8% of sales from 34.5% on spend discipline and lower acquisition and integration-related charges, offset by structural optimization charges

Cost of sales$2,091M-4.1% YoY

Benefited from reduction of certain import tariffs and lower amortization of inventory stepped up to fair value

Research, development and engineering$434M+6.6% YoY

6.6% of net sales, relatively flat with 6.8% in 2025

Amortization of intangible assets$175M-6.4% YoY

Margins: Gross margin rose to 68.3% from 63.8%, driven by a reversal of 2025 tariffs (260 bps) and lower inventory step-up amortization (110 bps). Operating margin reached 25.2% versus 18.5%.

Watch Items from the Filing

A $158M reversal of 2025 tariffs added 260 bps to gross margin and $0.34 to diluted EPS; management excludes it from adjusted results.
Vascular sales fell 0.7% to $496M (-1.8% constant currency), with United States Vascular down 6.7% — the only declining business.
Cybersecurity incident first reported March 11, 2026 caused idle production time raising manufacturing costs; forward-looking statements cite continuing uncertainty on operations and results.
Structural optimization and other special charges rose to $95M from $11M, including $70M of 'other charges' in the quarter.
Level 3 contingent consideration grew to $756M from $518M, including $271M from the AVS acquisition with up to $400M future milestones.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$6.6B

Net Income

Q2 2026

$1.3B

Free Cash Flow

Q2 2026

$1.1B

Operating Margin

Q2 2026

25.2%

ROIC

Q2 2026

17.1%

D/E Ratio

Q2 2026

0.62

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+11.2% YoY

$25.12BFY 2025

FY22 $18.45BFY23 $20.50BFY24 $22.59BFY25 $25.12B

Net Income

+8.5% YoY

$3.25BFY 2025

FY22 $2.36BFY23 $3.17BFY24 $2.99BFY25 $3.25B

Operating Income

+32.5% YoY

$4.89BFY 2025

FY22 $2.84BFY23 $3.89BFY24 $3.69BFY25 $4.89B

EPS (Diluted)

+8.2% YoY

$8.40FY 2025

FY22 $6.17FY23 $8.25FY24 $7.76FY25 $8.40

Total Assets

+11.3% YoY

$47.84BFY 2025

FY22 $36.88BFY23 $39.91BFY24 $42.97BFY25 $47.84B

Total Debt

+16.6% YoY

$15.86BFY 2025

FY22 $13.05BFY23 $12.99BFY24 $13.60BFY25 $15.86B

Op. Cash Flow

+18.9% YoY

$5.04BFY 2025

FY22 $2.62BFY23 $3.71BFY24 $4.24BFY25 $5.04B

Free Cash Flow

+22.8% YoY

$4.28BFY 2025

FY22 $2.04BFY23 $3.14BFY24 $3.49BFY25 $4.28B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$25.12B +11.2%	$22.59B +10.2%	$20.50B +11.1%	$18.45B +7.8%	$17.11B +19.2%	$14.35B
Net Income	$3.25B +8.5%	$2.99B -5.4%	$3.17B +34.2%	$2.36B +18.3%	$1.99B +24.7%	$1.60B
Operating Income	$4.89B +32.5%	$3.69B -5.1%	$3.89B +36.9%	$2.84B +9.9%	$2.58B +16.2%	$2.22B
EPS (Diluted)	$8.40 +8.2%	$7.76 -5.9%	$8.25 +33.7%	$6.17 +18.4%	$5.21 +24.0%	$4.20
Total Assets	$47.84B +11.3%	$42.97B +7.7%	$39.91B +8.2%	$36.88B +6.5%	$34.63B +0.9%	$34.33B
Total Debt	$15.86B +16.6%	$13.60B +4.6%	$12.99B -0.4%	$13.05B +4.6%	$12.48B -10.8%	$13.99B
Operating Cash Flow	$5.04B +18.9%	$4.24B +14.3%	$3.71B +41.4%	$2.62B -19.6%	$3.26B -0.4%	$3.28B
Free Cash Flow	$4.28B +22.8%	$3.49B +11.2%	$3.14B +54.0%	$2.04B -25.6%	$2.74B -1.9%	$2.79B

Get alerted when SYK's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for STRYKER CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SYK

BlackRock, Inc.
$8.6B27,414,742 sh
VANGUARD CAPITAL MANAGEMENT LLC
$7.1B22,536,843 sh
JPMORGAN CHASE & CO
$5.7B17,260,943 sh
STATE STREET CORP
$4.9B15,532,565 sh
GREENLEAF TRUST
$4.8B15,228,545 sh
PRICE T ROWE ASSOCIATES INC /MD/
$3.8B11,916,057 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.6B8,173,167 sh
WELLINGTON MANAGEMENT GROUP LLP
$2.6B8,167,185 sh
GEODE CAPITAL MANAGEMENT, LLC
$2.5B7,819,802 sh
MORGAN STANLEY
$1.9B5,960,732 sh

Fund	Value	Shares
BlackRock, Inc.	$8.6B	27,414,742
VANGUARD CAPITAL MANAGEMENT LLC	$7.1B	22,536,843
JPMORGAN CHASE & CO	$5.7B	17,260,943
STATE STREET CORP	$4.9B	15,532,565
GREENLEAF TRUST	$4.8B	15,228,545
PRICE T ROWE ASSOCIATES INC /MD/	$3.8B	11,916,057
VANGUARD PORTFOLIO MANAGEMENT LLC	$2.6B	8,173,167
WELLINGTON MANAGEMENT GROUP LLP	$2.6B	8,167,185
GEODE CAPITAL MANAGEMENT, LLC	$2.5B	7,819,802
MORGAN STANLEY	$1.9B	5,960,732

Companies Similar to SYK

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ABT

ABBOTT LABORATORIES

AI score

Highly similar · 40 shared holders

Capital Research Global Investors FLOSSBACH VON STORCH SE 1832 Asset Management L.P.

ABBV

AbbVie Inc.

AI score

Very similar · 38 shared holders

Capital Research Global Investors Boston Partners NORDEA INVESTMENT MANAGEMENT AB

JNJ

JOHNSON & JOHNSON

AI score

Very similar · 36 shared holders

Capital Research Global Investors Clearbridge Investments, LLC 1832 Asset Management L.P.

MDT

Medtronic plc

AI score

Very similar · 24 shared holders

Capital Research Global Investors Boston Partners National Pension Service

AMGN

AMGEN INC

AI score

Very similar · 31 shared holders

Capital Research Global Investors NORDEA INVESTMENT MANAGEMENT AB Boston Partners

BMY

BRISTOL MYERS SQUIBB CO

AI score

Very similar · 23 shared holders

NORDEA INVESTMENT MANAGEMENT AB National Pension Service PRIMECAP MANAGEMENT CO/CA/

LLY

ELI LILLY & Co

AI score

Very similar · 40 shared holders

PARNASSUS INVESTMENTS, LLC Capital Research Global Investors Clearbridge Investments, LLC

UNH

UNITEDHEALTH GROUP INC

AI score

Very similar · 30 shared holders

Capital Research Global Investors 1832 Asset Management L.P.Clearbridge Investments, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SYK on your watchlist

Track score changes the day STRYKER CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SYK a good stock to buy?

13F Pro's AI-powered analysis of STRYKER CORP (SYK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SYK are available on the SYK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SYK is classified as a large company.

Which hedge funds own SYK?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SYK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of STRYKER CORP's investment landscape.